GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2Results posted

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus

Lead sponsor

Eli Lilly and Company

Assets

Dulaglutide / Orforglipron

Listed sites

Recruiting sites

—

Enrollment

383

actual

Study population

Type 2 diabetes

Key I/E criterion

•BMI ≥23

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05048719

Org study ID17787

Secondary ID2021-002806-29

Secondary IDJ2A-MC-GZGEEli Lilly and Company

Timeline

Milestones

Study start2021-09-15actual

Study first posted2021-09-17actual

Primary completion2022-09-30actual

Study completion2022-09-30actual

Last update posted2023-10-17actual

Results first posted2023-10-17actual

Assets

Investigational agents

Dulaglutide Orforglipron

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin

•Have a stable body weight for the 3 months prior to randomization

•Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)

•Males must agree to use highly effective methods of contraception

•Women not of childbearing potential (WNOCBP) may participate in this trial

•Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion criteria

•Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma

•Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention

•Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms

•Have acute or chronic pancreatitis

•Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)

•Have gastric emptying abnormality or chronically take medications impacting GI motility

•Have poorly controlled hypertension

•Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure

•Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)

•Have HIV, or Hepatitis B or Hepatitis C

Endpoints (14)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Safety / tolerability / PK

Weight & body composition

2 endpoints

Secondary/registry result

Change From Baseline in Body Weight

Time frame:Baseline, Week 26

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
3 mg LY3502970	-3.7	—
12 mg LY3502970	-6.5	—
24 mg LY3502970	-9.7	—
36 mg LY3502970	-9.5	—
45 mg LY3502970	-10.1	—
Placebo	-2.2	—
1.5 mg Dulaglutide	-3.9	—

LS Mean Difference-1.695% CI-3.7 – 0.6p0.153Mixed Models Analysis

LS Mean Difference-4.395% CI-6.4 – -2.2p<0.001Mixed Models Analysis

LS Mean Difference-7.695% CI-9.8 – -5.3p<0.001Mixed Models Analysis

LS Mean Difference-7.495% CI-9.4 – -5.3p<0.001Mixed Models Analysis

LS Mean Difference-7.995% CI-9.9 – -5.9p<0.001Mixed Models Analysis

LS Mean Difference0.195% CI-2.0 – 2.3p0.914Mixed Models Analysis

LS Mean Difference-2.695% CI-4.7 – -0.5p0.015Mixed Models Analysis

LS Mean Difference-5.995% CI-8.1 – -3.6p<0.001Mixed Models Analysis

LS Mean Difference-5.795% CI-7.8 – -3.6p<0.001Mixed Models Analysis

LS Mean Difference-6.295% CI-8.3 – -4.2p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline, Week 26

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

10 endpoints

Primary/registry result

Change From Baseline in HbA1c in LY3502970 as Compared to Placebo

Time frame:Baseline, Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), Percentage of HbA1c	95% CI
3 mg LY3502970	-1.19	—
12 mg LY3502970	-1.91	—
24 mg LY3502970	-1.79	—
36 mg LY3502970	-2.03	—
45 mg LY3502970	-2.10	—
Placebo	-0.43	—

LS Mean Difference-0.7795% CI-1.13 – -0.40p<0.001Mixed Models Analysis

LS Mean Difference-1.4995% CI-1.85 – -1.12p<0.001Mixed Models Analysis

LS Mean Difference-1.3695% CI-1.75 – -0.98p<0.001Mixed Models Analysis

LS Mean Difference-1.6095% CI-1.96 – -1.25p<0.001Mixed Models Analysis

LS Mean Difference-1.6795% CI-2.02 – -1.32p<0.001Mixed Models Analysis

Primary/protocol endpoint

Change From Baseline in HbA1c in LY3502970 as Compared to Placebo

Time frame:Baseline, Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/registry result

Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide

Time frame:Baseline, Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), Percentage of HbA1c	95% CI
3 mg LY3502970	-1.19	—
12 mg LY3502970	-1.91	—
24 mg LY3502970	-1.79	—
36 mg LY3502970	-2.03	—
45 mg LY3502970	-2.10	—
1.5 mg Dulaglutide	-1.10	—

LS Mean Difference-0.0995% CI-0.47 – 0.28p0.626Mixed Models Analysis

LS Mean Difference-0.8195% CI-1.18 – -0.44p<0.001Mixed Models Analysis

LS Mean Difference-0.6995% CI-1.08 – -0.30p<0.001Mixed Models Analysis

LS Mean Difference-0.9395% CI-1.29 – -0.57p<0.001Mixed Models Analysis

LS Mean Difference-1.0095% CI-1.36 – -0.64p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants With HbA1c ≤ 6.5%

Time frame:Week 26

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), Percentage of participants	95% CI
3 mg LY3502970	45.30	—
12 mg LY3502970	70.73	—
24 mg LY3502970	80.12	—
36 mg LY3502970	79.39	—
45 mg LY3502970	83.52	—
Placebo	14.56	—
1.5 mg Dulaglutide	41.04	—

Odds Ratio (OR)6.7795% CI2.21 – 20.75p<0.001Regression, Logistic

Odds Ratio (OR)34.0995% CI9.92 – 117.16p<0.001Regression, Logistic

Odds Ratio (OR)48.3395% CI11.90 – 196.24p<0.001Regression, Logistic

Odds Ratio (OR)45.7295% CI13.61 – 153.64p<0.001Regression, Logistic

Odds Ratio (OR)77.2395% CI20.26 – 294.48p<0.001Regression, Logistic

Odds Ratio (OR)1.2295% CI0.48 – 3.13p0.678Regression, Logistic

Odds Ratio (OR)6.1595% CI2.19 – 17.24p<0.001Regression, Logistic

Odds Ratio (OR)8.7195% CI2.55 – 29.79p<0.001Regression, Logistic

Odds Ratio (OR)8.2495% CI3.05 – 22.30p<0.001Regression, Logistic

Odds Ratio (OR)13.9395% CI4.51 – 43.01p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants With HbA1c <7.0%

Time frame:Week 26

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), Percentage of participants	95% CI
3 mg LY3502970	65.17	—
12 mg LY3502970	78.92	—
24 mg LY3502970	91.24	—
36 mg LY3502970	92.75	—
45 mg LY3502970	95.76	—
Placebo	24.27	—
1.5 mg Dulaglutide	64.06	—

Odds Ratio (OR)8.1995% CI2.93 – 22.90p<0.001Regression, Logistic

Odds Ratio (OR)25.0295% CI7.57 – 82.69p<0.001Regression, Logistic

Odds Ratio (OR)62.3195% CI12.26 – 316.63p<0.001Regression, Logistic

Odds Ratio (OR)67.5795% CI17.56 – 259.97p<0.001Regression, Logistic

Odds Ratio (OR)129.5595% CI26.72 – 628.09p<0.001Regression, Logistic

Odds Ratio (OR)1.1395% CI0.43 – 2.96p0.802Regression, Logistic

Odds Ratio (OR)3.4695% CI1.16 – 10.31p0.026Regression, Logistic

Odds Ratio (OR)8.6195% CI1.83 – 40.51p0.006Regression, Logistic

Odds Ratio (OR)9.3495% CI2.67 – 32.71p<0.001Regression, Logistic

Odds Ratio (OR)17.9095% CI4.02 – 79.70p<0.001Regression, Logistic

Secondary/registry result

Change From Baseline in Fasting Serum Glucose

Time frame:Baseline, Week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligrams per deciliter (mg/dL)	95% CI
3 mg LY3502970	-32.6	—
12 mg LY3502970	-53.7	—
24 mg LY3502970	-52.2	—
36 mg LY3502970	-53.9	—
45 mg LY3502970	-55.9	—
Placebo	-11.1	—
1.5 mg Dulaglutide	-33.2	—

LS Mean Difference-21.595% CI-32.7 – -10.3p<0.001Mixed Models Analysis

LS Mean Difference-42.595% CI-53.4 – -31.7p<0.001Mixed Models Analysis

LS Mean Difference-41.095% CI-52.7 – -29.3p<0.001Mixed Models Analysis

LS Mean Difference-42.795% CI-53.5 – -32.0p<0.001Mixed Models Analysis

LS Mean Difference-44.795% CI-55.3 – -34.2p<0.001Mixed Models Analysis

LS Mean Difference0.695% CI-10.6 – 11.8p<0.001Mixed Models Analysis

LS Mean Difference-20.595% CI-31.4 – -9.5p<0.001Mixed Models Analysis

LS Mean Difference-19.095% CI-30.7 – -7.2p0.002Mixed Models Analysis

LS Mean Difference-20.795% CI-31.4 – -9.9p<0.001Mixed Models Analysis

LS Mean Difference-22.795% CI-33.2 – -12.1p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide

Time frame:Baseline, Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants With HbA1c ≤ 6.5%

Time frame:Week 26

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants With HbA1c <7.0%

Time frame:Week 26

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Fasting Serum Glucose

Time frame:Baseline, Week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

2 endpoints

Secondary/registry result

Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970

Time frame:Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

AUC₀–∞

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram hour per milliliter (ngh/mL)	95% CI
3 mg LY3502970	364	—
12 mg LY3502970	1020	—
24 mg LY3502970	1500	—
36 mg LY3502970 - 1	1830	—
36 mg LY3502970 - 2	2430	—
45 mg LY3502970 - 1	2230	—
45 mg LY3502970 - 2	2550	—

Secondary/protocol endpoint

Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970

Time frame:Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

AUC₀–∞

concentration, descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
Cardiovascular diabetology2025 Jun 6PMID40481478doi:10.1186/s12933-025-02781-xvia clinicaltrials gov reference derived + pubmed nct search
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet (London, England)2023 Aug 5PMID37369232doi:10.1016/S0140-6736(23)01302-8via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.